

**Meet the Network and Community Leadership**  
**Network: Translational and Precision Medicine (TPM)**  
**Community: Special Populations (SPO)**



**Community Vice Chair:**  
**Paulien Ravenstijn, PhD**  
Janssen R&D

Paulien Ravenstijn is Associate Scientific Director in the department of Global Clinical Pharmacology (GCP) at Janssen Research & Development in Beerse, Belgium. She obtained her PhD at Leiden University where she also obtained her MSc in Biopharmaceutical Sciences.

She is currently working as GCP Leader for early and late development compounds in the Neuroscience therapeutic area. She is responsible for the application of quantitative methods to integrate knowledge of pharmacokinetics (PK), pharmacodynamics (PD), patient characteristics, disease states, and drug—drug interactions to optimize dose selection, dosage regimens and study designs throughout drug development. Additionally, she is responsible for the appropriate summarization and interpretation of results of PK/PD analyses with respect to their impact on development and clinical use of drugs as well as to define the regulatory strategy for GCP.

In addition to her work as GCP Leader, she has developed a strong expertise and network in the field of pediatric drug development. She is the representative of Global Clinical Pharmacology in the Johnson & Johnson Pediatric Center of Excellence as well as the vice-chair in the Pediatric Working Group of the Clinical Pharmacology Leadership Group (CPLG) of the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ Consortium). Since this year, she is the vice-chair of the American Society for Clinical Pharmacology and Therapeutics Special Populations (ASCPT SPO) Steering Committee.